Marinkovic M, et al. - Researchers inquired regarding the role of Ruthenium-106 (Ru106) brachytherapy as an eye-conserving therapy of iris melanomas (IMs) and iridociliary melanomas (ICMs). This therapy exhibited remarkabgle local control (98.9%) and eye preservation (97.7%). Herein, the toxicities were common but mostly mild and transient. It was also observed that Ru106 did not exert an impact on the visual acuity.